NMNAT1 and glaucoma: Williams et al., in one of the most interesting experimental studies on glaucoma, reported that the oral supplementation of vitamin B3 (nicotinamide or niacin, a precursor of nicotinamide adenine dinucleotide (NAD+)) or Nmnat1 gene therapy prevented retinal ganglion cells soma loss in aged mice.